Slide 1Effect of Rosuvastatin Versus Placebo on Cardiovascular Outcomes in Patients with End-Stage Renal Disease on Hemodialysis – Results of the AURORA Study Bengt Fellström…

Slide 1Experience with Antibody-Mediated Rejection Millie Samaniego, M.D. Associate Professor of Medicine University of Wisconsin and Robert A. Montgomery, M.D., D.Phil.…

www.hks.harvard.edu How Long Do Treatment Effects Last? Persistence and Durability of a Descriptive Norms Intervention’s Effect on Energy Conservation Faculty Research…

Slide 1 Cost of & Access to Molecularly Targeted Therapies as Barriers to Optimal Care H. Jack West, MD Swedish Cancer Institute Seattle, WA Global Resource for Advancing…

Slide 1 PERINATAL MOOD DISORDERS: Update on Psychotropic Prescribing Slide 2 www.mainepsych.org Postpartum Depression Project Slide 3 Disclosures and Thanks Disclosures:…

Genitourinary Oncology ASCO 2009 Toni K. Choueiri, MD Dana-Farber Cancer Institute Harvard Medical School Boston, Massachusetts U.S.A. Bevacizumab plus Interferon-alpha versus…

Diapositiva 1 Lucio Crinò Medical Oncology Department University Hospital Perugia, Italy The optimal therapeutic algorithm for EML4-ALK + ve pts ‹N› “Anaplastic Lymphoma…

Bevacizumab plus Interferon-alpha versus Interferon-alpha Monotherapy in Patients with Metastatic Renal Cell Carcinoma: Results of Overall Survival for CALGB 90206 Brian…

Bevacizumab plus Interferon-alpha versus Interferon-alpha Monotherapy in Patients with Metastatic Renal Cell Carcinoma: Results of Overall Survival for CALGB 90206 Brian…

Slide 1 Surgery: Considerations and Research Sayeed Ikramuddin, MD First Annual Minnesota Pediatric Obesity Conference Practical Approaches for Managing and Preventing Pediatric…